Abstract PD3-10: Higher serum PD-L1 predicts for increased overall survival to lapatinib vs trastuzumab in the phase 3 CCTG MA.31 trial
Moku, PR, Shepherd, LE, Ali, SM, Leitzel, K, Parulekar, WE, Zhu, L, Virk, S, Nomikos, D, Aparicio, S, Gelmon, KA, Drabick, JJ, Cream, L, Halstead, SE, Umstead, T, Mckeone, D, Maddukuri, A, Polimera, HV, Ali, A, Poulose, J, Pancholy, N, Spiegel, H, Nagabhairu, V, Chen, BE, Lipton, A
Published in Cancer research (Chicago, Ill.) (15.02.2019)
Published in Cancer research (Chicago, Ill.) (15.02.2019)
Get full text
Journal Article